The Impella RP System is still associated with significant benefits, the FDA said, but there are certain high-risk patients who should no longer be eligible for treatment.

“There is a crucial need to develop synthetic vascular graft materials that will increase the rate of long-term functions,” one researcher said. Could materials derived from seaweed help fill that need?

A randomized study of more than 450 patients with persistent atrial fibrillation is now underway. All patients have been treated, and their outcomes will be tracked for 12 months. 

Getinge has provided a detailed breakdown of the shortage, stating that it is not yet clear when it may be over. The FDA said it will keep a close eye on the situation and provide updates when possible. 

This latest recall involves the device's driveline boot cover, which “can become stiff over time” and cause problems for clinicians. There have been 33 complaints since 2017 related to the issue.

A photo essay from the American Heart Association (AHA) 2022 Scientific Sessions Nov. 5-7 in Chicago.

VT storm is associated with a heightened risk of death or significant complications. Early catheter ablation, it seems, is the most effective treatment option for this potentially fatal condition. 

Integra LifeSciences Holding Corporation, a global medical technology company, has agreed to acquire Surgical Innovation Associates (SIA), which is known as the manufacturer of monofilament mesh for plastic and reconstructive surgery. The deal is valued up to $140 million.

Following the course, experts observed nearly perfect agreement between less experienced residents and chest-devoted radiologists.